A new trading day began on Friday, with Relay Therapeutics Inc (NASDAQ: RLAY) stock price down -4.16% from the previous day of trading, before settling in for the closing price of $4.09. RLAY’s price has ranged from $3.50 to $11.02 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 399.77% over the last five years. Meanwhile, its annual earnings per share averaged 10.10%. With a float of $125.39 million, this company’s outstanding shares have now reached $166.89 million.
The firm has a total of 323 workers. Let’s measure their productivity. In terms of profitability, gross margin is 58.64%, operating margin of -3926.55%, and the pretax margin is -3449.92%.
Relay Therapeutics Inc (RLAY) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Relay Therapeutics Inc is 25.09%, while institutional ownership is 76.24%. The most recent insider transaction that took place on Feb 11 ’25, was worth 539,701. In this transaction President and CEO of this company sold 140,182 shares at a rate of $3.85, taking the stock ownership to the 625,948 shares. Before that another transaction happened on Feb 13 ’25, when Company’s President and CEO sold 75,324 for $3.70, making the entire transaction worth $278,699. This insider now owns 883,089 shares in total.
Relay Therapeutics Inc (RLAY) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.62 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.79% during the next five years compared to -38.74% drop over the previous five years of trading.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
Here are Relay Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 18.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 65.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.61, a number that is poised to hit -0.56 in the next quarter and is forecasted to reach -2.62 in one year’s time.
Technical Analysis of Relay Therapeutics Inc (RLAY)
Analysing the last 5-days average volume posted by the [Relay Therapeutics Inc, RLAY], we can find that recorded value of 1.4 million was lower than the volume posted last year of 2.21 million. As of the previous 9 days, the stock’s Stochastic %D was 47.53%. Additionally, its Average True Range was 0.33.
During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 10.19%, which indicates a significant decrease from 24.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.51% in the past 14 days, which was lower than the 67.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.41, while its 200-day Moving Average is $6.19. Now, the first resistance to watch is $4.13. This is followed by the second major resistance level at $4.35. The third major resistance level sits at $4.45. If the price goes on to break the first support level at $3.81, it is likely to go to the next support level at $3.71. Should the price break the second support level, the third support level stands at $3.49.
Relay Therapeutics Inc (NASDAQ: RLAY) Key Stats
With a market capitalization of 656.14 million, the company has a total of 167,383K Shares Outstanding. Currently, annual sales are 25,550 K while annual income is -341,970 K. The company’s previous quarter sales were 0 K while its latest quarter income was -92,210 K.
